News >

Complete Lymph Node Dissection Not Superior to Surveillance in Melanoma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jan 30, 2018

Daniel Coit, MD

Daniel Coit, MD
For patients with melanoma who have positive sentinel lymph nodes (SLNs), practitioners now have phase III evidence that suggests that complete lymph node dissection (CLND) is not more effective than observation and nodal ultrasonography.

The international, multicenter, randomized MSLT-II trial evaluated the efficacy of CLND in melanoma patients with SLN metastases (n = 824) compared with that of observation and nodal ultrasonography (n = 931). In the per-protocol analysis and at median follow-up of 43 months, the mean 3-year rate of melanoma-specific survival (MSS) was similar in the dissection group (86 ± 1.3%) and the observation group (86 ± 1.2%), respectively (P = .42). The rate of disease-free survival was slightly higher in the dissection group than in the observation group (68 ± 1.7% and 63 ± 1.7%, respectively; P =.05) at 3 years.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20202.0
Publication Bottom Border
Border Publication